Nexavar improves survival in liver cancer

Published: 2008-06-17 07:00:00

Updated: 2008-06-17 07:00:00

Nexavar (sorafenib) tablets significantly improved overall survival by 47.3 percent in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC), according to Bayer HealthCare.

In a local symposium organized by the Korean Cancer Association, Dr. Tim F. Greten, Hannover S...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK